Dealing with the Deconstructors
While Big Pharma will continue to orchestrate the processes that move new compounds along the value chain from discovery to market, the value chain itself increasingly transcends company boundaries. A variety of new focused businesses, based on services and technologies, have emerged, differing greatly from the integrated model embraced by today's major players. Big Pharma's critical decisions about when to partner and when to compete with these new entrants will be based not only on the capabilities and market position of the new players but also on the strategies, culture and organization of traditional drug firms.
You may also be interested in...
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.
If President Donald Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsburg, Affordable Care Act coverage could disappear. Two legal experts weigh in on this and other legal issues that could touch the medical device industry.